Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 2006;107:1285-1291
© 2006 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeSimone, C. P.
Right arrow Articles by Modesitt, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeSimone, C. P.
Right arrow Articles by Modesitt, S. C.
Related Collections
Right arrow Cytology/colposcopy
Right arrow General gynecology
Right arrow Gynecologic oncology

ORIGINAL RESEARCH

Rate of Pathology From Atypical Glandular Cell Pap Tests Classified by the Bethesda 2001 Nomenclature

Christopher P. DeSimone, MD1, Misty E. Day, MD2, Molly M. Tovar, MD3, Charles S. Dietrich, III, MD1, Mary L. Eastham, MD4 and Susan C. Modesitt, MD1

From the 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, Lexington, Kentucky; 2Department of Obstetrics and Gynecology, University of Kentucky; 3Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky; and 4private practice, Mt. Sterling, Kentucky.

OBJECTIVE: To estimate the risk of significant pathology from atypical glandular cell (AGC) Pap tests classified by the 2001 Bethesda system and to assess potential differences in AGC management practices between physician specialties.

METHODS: A chart study was conducted to assess outcomes from AGC Pap tests diagnosed during 2001–2005.

RESULTS: One hundred thirty-one AGC Pap tests were identified from 84,748 Pap tests. The incidence of AGC was 0.15%. Thirty-nine AGC Pap tests (30%) were excluded from analysis, leaving 92 AGC Pap tests from 82 patients available for review. Thirty-one of 82 women (38%) had significant pathology. Seventeen women (21%) had preinvasive disease: cervical intraepithelial neoplasia 2 or 3, adenocarcinoma in situ and endometrial hyperplasia, whereas 14 women (17%) had invasive adenocarcinomas of the endometrium, cervix, ovary, and rectum. Women who were aged 40 years or younger differed significantly from women aged older than 40 years with regard to final pathology (P = .002). Specifically, they were more likely to have preinvasive disease and less likely to have invasive carcinoma. Recommended management for AGC includes colposcopy with or without biopsy, endocervical curettage, and endometrial biopsy. Sixty-three of 82 (77%) women were managed by recommended guidelines, and there was a statistically significant difference in physician adherence when comparing gynecologists to primary care physicians (87% compared with 50%, P < .001).

CONCLUSION: Atypical glandular cell cytology confers a risk (38%) of either preinvasive disease or carcinoma, with the risk of carcinoma increasing significantly for women aged older than 40. Adherence to recommended AGC management guidelines is crucial to identify underlying malignancies.

LEVEL OF EVIDENCE: II-2




This article has been cited by other articles:


Home page
Obstet GynecolHome page
J. B. Hall
Rate of pathology from atypical glandular cell pap tests classified by the bethesda 2001 nomenclature.
Obstet. Gynecol., October 1, 2006; 108(4): 1034 - 1034.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Obstetricians and Gynecologists.